Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    NGM Biopharmaceuticals In...

    NASDAQ: NGM · Real-Time Price · USD
    1.54
    -0.02 (-1.28%)
    At close: Apr 03, 2024, 3:59 PM

    NGM Biopharmaceuticals Statistics

    Share Statistics

    NGM Biopharmaceuticals has 83.46M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 83.46M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 3,367

    FTD / Avg. Volume

    n/a
    		 0.31%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -0.5 and the forward PE ratio is null. NGM Biopharmaceuticals's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -0.5

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 16.04

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.48

    P/FCF Ratio

    n/a
    		 -0.53

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    NGM Biopharmaceuticals has an Enterprise Value (EV) of 12.05M.

    EV / Sales

    n/a
    		 2.73

    EV / EBITDA

    n/a
    		 -0.08

    EV / EBIT

    n/a
    		 -0.09

    EV / FCF

    n/a
    		 -0.09

    Financial Position

    The company has a current ratio of 7.79, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 7.79

    Quick Ratio

    n/a
    		 7.79

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is -95.79% and Return on Invested Capital is -98.59%.

    Return on Equity

    n/a
    		 -95.79%

    Return on Assets

    n/a
    		 -84.31%

    Return on Invested Capital

    n/a
    		 -98.59%

    Revenue Per Employee

    n/a
    		 $32,007.25

    Profits Per Employee

    n/a
    		 $-1,031,702.9

    Employee Count

    n/a
    		 138

    Asset Turnover

    n/a
    		 0.03

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 1.26, so NGM Biopharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.26

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 1.55

    200-Day Moving Average

    n/a
    		 1.52

    Relative Strength Index (RSI)

    n/a
    		 48.53

    Average Volume (20 Days)

    n/a
    		 1,070,739

    Income Statement

    In the last 12 months, NGM Biopharmaceuticals had revenue of 4.42M and earned -142.38M in profits. Earnings per share was -1.73.

    Revenue

    n/a
    		 4.42M

    Gross Profit

    n/a
    		 2.2M

    Operating Income

    n/a
    		 -146.55M

    Net Income

    n/a
    		 -142.38M

    EBITDA

    n/a
    		 -144.33M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -1.73
    Full Income Statement

    Balance Sheet

    The company has 58.81M in cash and 0 in debt, giving a net cash position of 58.81M.

    Cash & Cash Equivalents

    n/a
    		 58.81M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -724.01M

    Total Assets

    n/a
    		 168.87M

    Working Capital

    n/a
    		 136.36M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -132.2M and capital expenditures -1.25M, giving a free cash flow of -133.45M.

    Operating Cash Flow

    n/a
    		 -132.2M

    Capital Expenditures

    n/a
    		 -1.25M

    Free Cash Flow

    n/a
    		 -133.45M

    FCF Per Share

    n/a
    		 -1.62
    Full Cash Flow Statement

    Margins

    Gross margin is 49.72%, with operating and profit margins of -3317.79% and -3223.34%.

    Gross Margin

    n/a
    		 49.72%

    Operating Margin

    n/a
    		 -3317.79%

    Pretax Margin

    n/a
    		 -3223.34%

    Profit Margin

    n/a
    		 -3223.34%

    EBITDA Margin

    n/a
    		 -3267.51%

    EBIT Margin

    n/a
    		 -3317.79%

    FCF Margin

    n/a
    		 -3021.37%

    Dividends & Yields

    NGM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -200.91%

    FCF Yield

    n/a
    		 -188.32%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for NGM.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -4.17

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist